MUMBAI – Cash flow uncertainty clouds the prospects for Indian drug companies to transition to a research-driven approach, as evidenced on a March 25 investor call by Sun Pharma Advanced Research Co. Ltd. (SPARC) – the carved-out, listed research entity of Sun Pharmaceutical Industries Ltd.
Delays in meeting product development and launch timelines have made investors wary about the likely upsides from the late-stage pipeline...